The Latest Breaking News from FDA

MIAMI — A Broward health company’s weight loss pill caught the attention of the FDA after the regulatory agency found it contained a drug that was taken off the market more than a decade ago for possibly causing severe health risks.

"The drugs so far appear to be quite effective."

Washington (AFP) - A conservative Texas judge is poised to rule on whether to impose a nationwide ban on a drug used for more than half of the abortions in the United States.

A Texas lawsuit could threaten the nationwide availability of medication abortion, which now accounts for the majority of abortions in the U.S. The case filed by abortion opponents who helped challenge Roe v. Wade seeks to reverse a decades-old approval by the Food and Drug Administration

New research is exploring whether psychedelic drugs, taken under strict medical supervision, might help in treating post-traumatic stress disorder, chronic pain, depression and obsessive-compulsive disorder. SciLine interviewed Dr. Jennifer Mitchell – a professor in the Departments of Neurology and Psychiatry Behavioral Science in the School of Medicine at the University…

Post-Roe, women’s access to contraception is more important than ever. But Perrigo's HRA Pharma is still waiting to hear back from the FDA.

Although the Fed is expected to go slow with rate hikes, they are not expected to end anytime soon. Moreover, the possibility of a recession cannot be ruled out yet. Given the uncertainties, fundamentally sound dividend stocks Pfizer (PFE) and Sisecam (SIRE) could be a solid addition to your portfolio…

163% more women would lose access to abortion care if the FDA's approval of mifepristone is revoked.

Deputy Prime Minister Dominic Raab said he is 'confident' he has 'behaved professionally at all times' after civil servants who worked for him warned they had lost weight, suffered breakdowns or even felt suicidal

The Deputy Prime Minister has said that the allegations against him published in the media were ‘mostly incorrect’.

Judge Matthew Kacsmaryk has amassed a litany of contentious rulings in less than four years